Shanghai HeartCare Medical Technology Corporation Ltd. has announced a significant positive shift in its financial performance for the year ended December 31, 2025. Based on a preliminary review of unaudited consolidated management accounts, the company expects its revenue to be in the range of RMB400.0 million to RMB410.0 million, reflecting an increase of at least 43.9% compared to RMB277.9 million in 2024. Additionally, the company anticipates recording a profit before tax of approximately RMB80.0 million for the period, marking a substantial turnaround from a net loss before tax of RMB12.0 million in the previous year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai HeartCare Medical Technology Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260120-11996459), on January 20, 2026, and is solely responsible for the information contained therein.